IP Library › Granted Patent US 12,692,396
Granted Patent B2
US 12,692,396 · App. 17/915,474 · Granted Jul 28, 2026

Fluorescent labeling agent and fluorescent dye

Inventors: Rino Yokokura (Tokyo, JP); Ryutaro Yamamoto (Tokyo, JP); Hidenori Minashima (Tokyo, JP)
Assignee: artience Co., Ltd.
C09B47/045C07F5/06C07F5/062C07F5/064C07F5/065C07F5/066C07F5/067C07F5/069C09K11/06G01N21/6428G01N33/582C09K2211/1096C09K2211/186G01N2021/6439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,692,396
App. No.
17/915,474
Granted
Jul 28, 2026
Kind
B2
Abstract

A fluorescent labeling agent contains a fluorescent dye represented by general formula (1). General formula (1): Q-Z—R 1 —R 2 —R 3 (In the formula, Q represents the residue of a fluorescent dye. Z represents a direct bond, alkylene group, or arylene group. R 1 represents a direct bond, —O—, —OP(═O)R 4 —, —OC(═O)—, —OS(═O) 2 —, —OSiR 5 R 6 —, —C(═O)—, or —C(═O)NH—. R 2 represents a group selected from the group consisting of alkylene groups, arylene groups, and heterocyclic groups, or represents a group provided by combining these groups. R 3 represents —COOM 1 , —NR 7 R 8 , or —N + R 9 R 10 R 11 . Here, R 4 represents a hydrogen atom, hydroxyl group, alkyl group, aryl group, alkoxy group, aryloxy group, or heterocyclic group. R 5 and R 6 each independently represent an alkyl group, aryl group, or heterocyclic group. R 7 -R 11 each independently represent a hydrogen atom, alkyl group, or aryl group. M 1 represents a monovalent cation).

Claims (49)

1 . A fluorescent labeling agent comprising:

a fluorescent dye containing a phthalocyanine dye represented by the following general formula (2),

here, X 1 -X 16 each independently represent —Z—R 1 —R 2 —R 3 , a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted heterocyclic group, -AB, —SO 3 M 5 , or —COOM 6 ,

in the -AB, A represents a Group 16 element, B represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, or a substituted or unsubstituted heterocyclic group,

the M 5 and M 6 each independently represent a monovalent cation, or

in the X 1 -X 16 , adjacent substituents may be linked to each other to form a ring,

X 17 represents —Z—R 1 —R 2 —R 3 , a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, —OP(═O)X 18 X 19 , —OC(═O)X 20 , —OS(═O) 2 X 21 , or —OSiX 22 X 23 X 24 ,

the X 18 and X 19 each independently represent a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, or a substituted or unsubstituted heterocyclic group,

the X 20 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group,

the X 21 represents a hydroxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group,

the X 22 -X 24 each independently represent a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group,

Y represents a trivalent to pentavalent metal atom, and k is an integer, in a case where Y is a trivalent metal atom, k is 1, and, in a case where Y is a tetravalent or pentavalent metal atom, k is 2,

here, at least one of X 1 -X 17 is —Z—R 1 —R 2 —R 3 ,

Z represents a direct bond, a substituted or unsubstituted alkylene group, or a substituted or unsubstituted arylene group,

R 1 represents —OP(═O)R 4 —, —OC(═O)—, —OS(═O) 2 —, —C(═O)—, or —C(═O)NH—,

R 2 represents a group selected from the group consisting of unsubstituted alkylene groups, substituted or unsubstituted arylene groups, and substituted or unsubstituted heterocyclic groups, or represents a group provided by combining these groups,

R 3 represents —COOM 1 , —NR 7 R 8 , —OM 2 , or —P(═O)(OM 3 )OM 4 ,

the R 4 represents a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, or a substituted or unsubstituted heterocyclic group,

the R 7 -R 8 each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group, and

the M 1 , M 2 , M 3 , and M 4 each independently represent a hydrogen atom or a monovalent cation.

2 . The fluorescent labeling agent according to claim 1 that is a phospholipid accumulation-type fluorescent labeling agent.

3 . The fluorescent labeling agent according to claim 1 ,

wherein X 17 in the general formula (2) is —Z—R 1 —R 2 —R 3 .

4 . A compound represented by the following general formula (3),

here, X 1 -X 16 each independently represent —Z—R 1 —R 2 —R 3 , a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted heterocyclic group, -AB, —SO 3 M 5 , or —COOM 6 ,

in the -AB, A represents a Group 16 element, B represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, or a substituted or unsubstituted heterocyclic group,

the M 5 and M 6 each independently represent a monovalent cation, or

in the X 1 -X 16 , adjacent substituents may be linked to each other to form a ring,

X 17 represents —Z—R 1 —R 2 —R 3 , a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, —OP(═O)X 18 X 19 , —OC(═O)X 2 O, —OS(═O) 2 X 21 , or —OSiX 22 X 23 X 24 ,

the X 18 and X 19 each independently represent a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, or a substituted or unsubstituted heterocyclic group,

the X 20 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group,

the X 21 represents a hydroxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group,

the X 22 -X 24 each independently represent a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group,

Y represents a trivalent to pentavalent metal atom, and k is an integer, in a case where Y is a trivalent metal atom, k is 1, and, in a case where Y is a tetravalent or pentavalent metal atom, k is 2,

here, at least one of X 1 -X 17 is —Z—R 1 —R 2 —R 3 ,

here, Z represents a direct bond, a substituted or unsubstituted alkylene group, or a substituted or unsubstituted arylene group,

R 1 represents —OP(═O)R 4 —, —OC(═O)—, —OS(═O) 2 —, —C(═O)—, or —C(═O)NH—,

R 2 represents a group selected from the group consisting of unsubstituted alkylene groups, substituted or unsubstituted arylene groups, and substituted or unsubstituted heterocyclic groups, or represents a group provided by combining these groups,

R 3 represents —COOM 1 , —NR 7 R 8 , —OM 2 , or P(═O)(OM 3 )OM 4 ,

the R 4 represents a hydrogen atom, a hydroxyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, or a substituted or unsubstituted heterocyclic group,

the R 7 -R 8 each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group, and

the M 1 , M 2 , M 3 , and M 4 each independently represent a hydrogen atom or a monovalent cation.

5 . The fluorescent labeling agent of claim 1 , wherein

in General Formula (2),

X 17 represents —Z—R 1 —R 2 —R 3 ,

Z represents a direct bond,

R 1 represents —OP(═O)R 4 —,

R 3 represents —COOM 1 , and

the M 1 represents a hydrogen atom or a monovalent cation.

Assignments (2)
CHANGE OF NAME Recorded Feb 19, 2024
From: TOYO INK SC HOLDINGS CO., LTD.
To: ARTIENCE CO., LTD.
Reel/Frame 066625/0611 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2022
From: YOKOKURA, RINO; YAMAMOTO, RYUTARO; MINASHIMA, HIDENORI
To: TOYO INK SC HOLDINGS CO., LTD.
Reel/Frame 061263/0489 →
Priority Claims (1)
JP 2020-066924 · Apr 2, 2020 · national
Continuity (1)
Related Publication 20230145826A1 · May 11, 2023
References Cited (45)
US 5135717A · Renzoni · 1992 [cited by examiner]
US 5166197A · Kenney · 1992 [cited by examiner]
US 5438135A · Tai et al. · 1995 [cited by applicant]
US 5627028A · Tai et al. · 1997 [cited by applicant]
US 6060598A · Devlin et al. · 2000 [cited by applicant]
US 20090304598A1 · Gray · 2009 [cited by applicant]
US 20120323164A1 · Kenney et al. · 2012 [cited by applicant]
US 20140369935A1 · Okamoto et al. · 2014 [cited by applicant]
US 20190015510A1 · Makings et al. · 2019 [cited by applicant]
US 20230145826A1 · Yokokura et al. · 2023 [cited by applicant]
US 20240376378A1 · Yamamoto · 2024 [cited by examiner]
CN 1583762A · 2005 [cited by examiner]
CN 103539799A · 2014 [cited by examiner]
CN 103874482 · 2014 [cited by applicant]
CN 109081852 · 2018 [cited by applicant]
JP 02048991A · 1990 [cited by examiner]
JP 05124354A · 1993 [cited by examiner]
JP H05163439 · 1993 [cited by applicant]
JP H05194942 · 1993 [cited by applicant]
JP H06200177 · 1994 [cited by applicant]
JP 2008209361 · 2008 [cited by applicant]
JP 2009524580 · 2009 [cited by applicant]
JP 2019172826 · 2019 [cited by applicant]
JP 2019218374 · 2019 [cited by applicant]
JP 2020023676 · 2020 [cited by applicant]
JP 2020177014 · 2020 [cited by applicant]
JP 2021193353 · 2021 [cited by applicant]
WO 2004038378 · 2004 [cited by applicant]
WO 2013051732 · 2013 [cited by applicant]
WO 2021201284 · 2021 [cited by applicant]
Eckert et al., Angewandte Chemie (1981), 93(5), pp. 477-479. (Year: 1981). [cited by examiner]
A Human assisted English translation of Eckert et al., Angewandte Chemie (1981), 93(5), pp. 477-479. (Year: 1981). [cited by examiner]
A Human assisted English translation of JP 02-048991 A (Kashima), 1990. (Year: 1990). [cited by examiner]
Chemical Abstracts Registry No. 2306688-28-6, indexed in the Registry file on STN CAS Online May 9, 2019. (Year: 2019). [cited by examiner]
A machine generated English translation of Tamano et al. , JP 05-124354 A, 1993. (Year: 1993). [cited by examiner]
“Office Action of China Counterpart Application”, issued on Mar. 13, 2024, with English translation thereof, p. 1-p. 23. [cited by applicant]
“Search Report of Europe Counterpart Application”, issued on Mar. 26, 2024, p. 1-p. 7. [cited by applicant]
“Decision of Rejection of China Counterpart Application”, issued on Jan. 9, 2025, with English translation thereof, p. 1-p. 15. [cited by applicant]
“Office Action of China Counterpart Application”, issued on Aug. 1, 2024, with English translation thereof, p. 1-p. 14. [cited by applicant]
“Office Action of Japan Counterpart Application”, issued on Aug. 22, 2023, with English translation thereof, p. 1-p. 8. [cited by applicant]
“Office Action of Japan Counterpart Application”, issued on Jan. 30, 2024, with English translation thereof, p. 1-p. 6. [cited by applicant]
“International Search Report (Form PCT/ISA/210) of PCT/JP2021/014351”, mailed on May 11, 2021, with English translation thereof, pp. 1-6. [cited by applicant]
Yuki Takahashi et al., “In vivo fate of exogenously-administered exosomes,” Drug Delivery System, Jun. 2014, pp. 116-124. [cited by applicant]
“Search Report of Europe Counterpart Application”, issued on Sep. 19, 2025, p. 1-p. 8. [cited by applicant]
“Trial and Appeal Decision of Japan Counterpart Application”, issued on Jan. 20, 2026, with English translation thereof, p. 1-p. 59. [cited by applicant]